Baar, Switzerland, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Medela, a global leader in healthcare technology, today announced the expansion of Drainology™, a scientific initiative dedicated to advancing evidence-based chest drain management through research, education and clinical collaboration. With new digital channels, expert-led educational resources and scientific events, the initiative will broaden access to knowledge and create additional opportunities for exchange and collaboration across the global healthcare community.

Drainology™ will also be featured as part of Medela’s presence at the 40th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting, taking place October 7–10, 2026, in Barcelona, Spain.
Although chest drainage therapy is a fundamental component of cardiothoracic care, clinical practice continues to vary across healthcare settings. Drainology™ aims to support healthcare professionals by providing an evidence-based platform for education, expert dialogue, and practical insights.
Guided by an independent scientific board and sponsored by Medela, Drainology™ was established to encourage scientific exchange, promote evidence-based approaches, and help translate emerging knowledge into clinical practice.
Through Drainology™, Medela reinforces its commitment to clinical excellence in chest drainage therapy by supporting the generation, dissemination and application of scientific evidence. It serves as a global resource for clinicians who seek to strengthen decision-making, reduce practice variability and improve patient outcomes.
“At Medela, we know that technology alone does not improve patient care. Clinicians also need access to strong evidence, clinical expertise, and exchange with their peers,” said Thomas Golücke, CEO of Medela. “With Drainology™, we want to help advance the science of chest drain management, bring these elements together and support healthcare professionals in translating the latest knowledge into everyday practice. This reflects Medela’s broader commitment to combining clinical understanding with solutions that enable more informed and effective care and ultimately improve the patient experience.”
Through Drainology™, Medela collaborates with leading specialists in cardiothoracic surgery to foster scientific dialogue, support clinical decision-making through literature reviews and expert insights, share evidence-based knowledge and promote best practices in chest drain management.
The Drainology™ initiative is supported by an independent scientific board comprising Stephen D. Cassivi, Daniel Engelman, Wentao Fang, Eric Lim, Kevin W. Lobdell, Gloria Färber, and Alan D. L. Sihoe. The board provides expert guidance on educational and scientific activities, while Medela serves as sponsor and provides operational support.
"The future of cardiac surgery chest drain management must evolve from tradition to precision through networked learning and AI-augmented care. When we replace habit with continuous, data-driven insights, we will reduce complications like Retained Blood Syndrome and enhance recovery," said Kevin W. Lobdell, MD, Professor & System Director CV Surgical Quality, Education, and Research at Atrium Health, and Drainology™ board member.
Creating a Global Hub for Scientific Exchange in Chest Drain Management
Drainology™ provides healthcare professionals with access to expert-led educational content, scientific resources and opportunities for collaboration and global best-practice sharing. Through scientific sessions and symposia at leading conferences, as well as its website, newsletter, and LinkedIn presence, the initiative aims to facilitate scientific dialogue, encourage collaboration across the global healthcare community and support the continued advancement of chest drain management.
Healthcare professionals are encouraged to visit www.drainology.org, follow the Drainology™ LinkedIn page, and subscribe to the Drainology™ newsletter for educational content, expert perspectives, and updates from the platform.
About Medela
Through advancing research, observing natural behavior and listening to our customers, Medela turns science into care while nurturing health for generations. Medela supports millions of moms, babies, patients and healthcare professionals in more than 100 countries all over the world. As the healthcare choice for more than 6 million hospitals and homes across the globe, Medela provides leading research-based breast milk feeding products, healthcare solutions for hospitals, and clinical education. Medela is dedicated to building better health outcomes, simplifying and improving life, and developing breakthroughs that help moms, babies and patients live their life to the fullest. For more information, visit medela.com.
Attachment
-
药明康德连续三年荣获 EcoVadis“金牌”,跻身全球受评企业前5%上海2026年10月8日 美通社 -- 药明康德今日宣布,公司连续第三年获得国际可持续发展评估权威机构 EcoVadis授予的 “金牌”。这一认可充分体现了公司对可持续发展的2026-10-08
-
BLACKYAK发布品牌企划“INVISIBLE WHITE”:“危急时刻现身雪山的白色魅影”* 将在危急时刻现身、完成任务后又消失于风雪之中的山地救援队,比作“白色雪山魅影(Ghosts of the White Mountain)” * 品牌大片讲述BLACKYAK品牌大使Hannah Quat2026-10-08
-
2026年度THE 50 BEST BARS“THE 50最佳酒吧”榜单隆重揭晓香港BAR LEONE蝉联THE WORLD‘S BEST BAR“世界最佳酒吧”宝座 * 香港Bar Leone荣膺由巴黎水Perrier赞助的The World’s Best Bar“世界最佳酒吧”及The Best B2026-10-08
-
ICANN 公布 2026 轮次新通用顶级域名申请情况申请情况反映出全球各界对增加域名系统选择、促进竞争的广泛关注 洛杉矶2026年10月8日 美通社 -- 负责协调域名系统(DNS)的非营利组织 Internet Corporation for Ass2026-10-08
-
YYForce 在新加坡启用机器人中心,推进人形机器人训练与服务机器人部署战略里程碑:正式启用位于新加坡的机器人训练、数据与体验中心,为人形机器人训练、工作流程测试和客户演示提供支持。 把握 681 亿美元市场机遇:抓住全球服务机器2026-10-08
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐
-
2026 雷瓦亮相京东 MALL ,匠心筑造专业造型新标杆
